Law firms Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’ Sophie Chan · 9 February 2024 · 3 min read Profile Life Sciences Yearbook 2024 McDermott Will & Schulte David Gibson, senior associate at McDermott Will & EmeryWhy did you decide to specialise in life sciences law, and what’s the best thing about being a life sciences lawyer?Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryTrading Places: White & Case hires Mayer Brown funds head as former Freshfields US disputes head decamps for DLALaw firmsEliza Winter21 Aug 2026Simmons taps McDermott for former Schulte funds partnerLaw firmsKate Peacock13 Aug 2026Trading Places: A&O Shearman energy and infra co-head moves to DLA as Linklaters builds in New York with Paul Weiss hireLaw firmsKate Peacock7 Aug 2026M&A perspectives: Melissa FogartyLaw firmsIman Tribak26 Jun 2024M&A perspectives: Jennifer BethlehemLaw firmsIman Tribak26 Jun 2024M&A perspectives: Lorenzo CorteLaw firmsIman Tribak26 Jun 2024Sponsored thought leadership: China life sciences – Transaction insights and notable industry trendsPractice areasGuest Blog9 Feb 2024The Legal 500 view: Healthy competitionLaw firmsBen Wheway9 Feb 2024Life Sciences Yearbook 2024 – Editor’s letterPractice areasGeorgina Stanley9 Feb 2024